The immune system plays an important role in distinguishing self from non-self-including those T cells that possess the capacity to recognize self-antigens and eliminate abnormal or malignant cells. In this study, we aimed to identify autoantigens associated with ovarian cancer and study their potential to elicit a T cell response. Protein arrays consisting of 9184 self-proteins were used to screen for the presence of autoantibodies in sera from ovarian cancer patients, which led to the identification of two new protein targets of interest, P1 and P2 [1]. Alongside these antigens, heat shock factor-1 (HSF-1) has been previously identified as an autoantigen of interest through the presence of autoantibodies [2]. The presence of class-switched IgG and IgA antibodies to all three antigens indicated that these may have been the consequence of T-cell-dependent responses and suggested the existence of potentially autoreactive T cells to these same antigens. Therefore, identified proteins were epitope-mapped for activating T cells, and predicted binding was calculated for HLA class I and class II. The top predicted CD4 and CD8 T-cell peptide epitopes were synthesized and progressed for testing for antigenicity in an enhanced-sensitivity interferon-gamma (IFN-γ) chromogenic enzyme-linked immunospot (ELISpot). The results identified multiple new epitopes in all three proteins, including the two novel proteins that can elicit antigen-specific T-cell responses in peripheral blood mononuclear cells (PBMCs) derived from healthy donors. These potential candidates will be explored in the future for their role in the prevention or elimination of cancers that express the novel P1 and P2 protein targets. The ability of healthy immune systems to recognize these antigens further highlights their potential in the development of new therapeutic vaccines aimed at improving outcomes for ovarian cancer patients.